Studies and case studies have shown that Milmed contributes to reduced allergic problems to pollen and fur. Two studies have also shown that Milmed has given positive results in the treatment of pollen and fur allergies.
Our allergy patent was approved in October 2020 and we are now preparing for a Phase I clinical trial. We are working to ensure that the clinical trial can begin in Q2 2022. All of our treatment areas fit into the same Phase I study, which is a great advantage. Since we already have proven through in vitro-studies at Sapienza that Milmed contains zero toxicity, we are certain that this clinical trial will run smoothly.
Bergenstråhle & Partners has conducted an IP valuation of our allergy patent and you can read the report here.
In 2020 we published two articles in The Journal of Immunology and Allergy which you can find through the links below.